NCT01565746View on ClinicalTrials.gov

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

April 30, 2016

Conditions
Prostatic Neoplasms
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg

Trial Locations (3)

277-8577

Kashiwa

236-0004

Yokohama

589-8511

Sayama

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01565746 - Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients | Biotech Hunter | Biotech Hunter